XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. Janus kinase one (JAK1) plays a central role in the signaling pathways of several inflammatory cytokines.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

SEPTEMBER 2, 2020

VK2809 is a novel, oral small molecule thyroid hormone receptor beta agonist that has selectivity for liver tissue. It is now seen as an epidemic within chronic liver disease, particularly as its prevalence has been increasing and paralleling that of obesity, making it a major health concern worldwide.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

XTalks

FEBRUARY 21, 2025

In the gut, these receptors prompt the release of hormones such as cholecystokinin and GLP-1, which together signal satiety. In a Phase II trial involving patients with hyperphagia, ARD-101 was well tolerated and achieved an approximate eight-point reduction in hunger scores. The competitive landscape is equally dynamic.

Genetics 59

Genetics Hormones Gene Expression Gene 59

XTalks

NOVEMBER 21, 2024

These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. It’s the first and only approved dual agonist targeting both the GIP and GLP-1 receptors.

Sales 105

Sales Insulin Drugs Trials 105

XTalks

OCTOBER 25, 2023

Neal-Perry spoke about some of the latest trial data for fezolinetant that was presented at the recent Annual Meeting of The Menopause Society. This includes the effect of the drug on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history from pooled data from two randomized Phase III studies.

Life Science 52

Life Science Trials FDA Approval Hormones 52

XTalks

DECEMBER 13, 2024

Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas. By mimicking this hormone, petrelintide may offer an alternative or complement to incretin-based therapies, known for their role in weight management.

Drugs 102

Drugs Hormones Trials Clinical Trials 102

XTalks

JANUARY 29, 2025

Related: Eli Lillys Zepbound Approved as First Treatment for Obstructive Sleep Apnea The commercial describes Zepbounds mechanism of action as a dual receptor against that works by activating two naturally occurring hormone receptors in [the] body [GLP-1 and GIP-1]. Its changing how much weight I lose, up to 48 lbs, he says.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105

Hormones Antibody Trials Production 105

XTalks

NOVEMBER 29, 2023

David Cameron, Chair of the Breast International Group (BIG) , we delve into the landscape of breast cancer research today, clinical trials and the incorporation of the patient voice in breast cancer research. Breakthroughs in Treatment BIG has been at the forefront of numerous clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

XTalks

JULY 17, 2024

Sweden-based biotech Camurus shared positive Phase III trial data for CAM2029, one of its lead candidates, in patients with the rare hormonal disorder acromegaly. Due to its ability to mimic somatostatin, octreotide is used to treat various conditions associated with excessive hormone production.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. The results still require further validation, including experimental and clinical evaluation. The list also included melatonin.

Research 98

Research Hormones Protein Regulation 98

XTalks

MARCH 8, 2021

GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. Semaglutide acts by inhibiting glucagon, which is a hormone that increases blood sugar. It combines the action of both glucose-lowering metabolic hormones into a single molecule.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

DECEMBER 5, 2024

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. percent in the 68-week STEP-1 clinical trial.

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

XTalks

JANUARY 23, 2024

Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development. This rare endocrine disorder, characterized by inadequate secretion of growth hormone from the pituitary gland, has profound impacts on physical and sometimes cognitive development.

Development 72

Development Hormones Drugs Trials 72

XTalks

MAY 27, 2022

This result came from the promising Phase III EMERALD global clinical trial ( NCT03778931 ). Recent studies in mouse models implanted with human tumor cells (xenografts) have shown that elacestrant exhibits significant anti-tumor activity , even in ESR1 mutated models resistant to hormone therapy. This oral drug binds to ER? —

Clinical Trials 98

Clinical Trials Clinical Trials Trials Gene 98

XTalks

DECEMBER 5, 2024

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. percent in the 68-week STEP-1 clinical trial.

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

XTalks

NOVEMBER 9, 2022

GLP-1 receptor agonists, or incretin (metabolic hormones) mimetics, are analogs of the GLP-1 peptide hormone that binds to the GLP-1 receptor to regulate blood sugar levels by boosting insulin secretion. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

JUNE 16, 2023

Notably, the EMPA-KIDNEY Phase III clinical trial results published in The New England Journal of Medicine revealed that Jardiance (empagliflozin), an SGLT2 inhibitor, significantly reduced the risk of kidney disease progression or death from cardiovascular causes compared to placebo in patients with pre-existing CKD.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Hormones 96

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. Hormone-based therapeutics aim to delay glaucoma progression by enhancing estrogen’s potential protective effects.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

FEBRUARY 3, 2023

Aditya Bardia, MD, MPH, director of Breast Cancer Research at Mass General Cancer Center, associate professor at the Medicine Department at Harvard Medical School and principal investigator for the EMERALD trial, in the same press release statement. Mutations in the ESR1 , however, have contributed to the rise of endocrine resistance.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

XTalks

MAY 23, 2024

For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.

Clinical Trials 52

Clinical Trials Clinical Trials Hormones Trials 52

XTalks

SEPTEMBER 12, 2024

Although still in early clinical trials, this immunotherapy approach could represent a significant advance for patients with limited treatment options. Make an Impact on Prostate Cancer Awareness Month 2024 Ongoing research and clinical trials are bringing the medical community closer to more effective treatments.

Research 52

Research Clinical Trials Clinical Trials Hormones 52

XTalks

NOVEMBER 10, 2021

In the ASCEND trials, Daprodustat was comparable to Amgen’s Aranesp (darbepoetin alfa), an erythropoiesis-stimulating agent (ESA), with respect to heart safety. Darbepoetin alfa is a synthetic version of the hormone erythropoietin, which is made in the kidneys and stimulates the production of red blood cells (RBC), or erythrocytes.

Trials 97

Trials Hormones Drugs FDA Approval 97

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

NOVEMBER 5, 2024

This funding infusion is poised to support Septerna’s expanding pipeline and ongoing clinical trials within its core therapeutic areas. SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance. Phase I trials are underway, with data expected in mid-2025.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes.

Vaccine 103

Vaccine Vaccination Insulin Trials 103

XTalks

JULY 2, 2021

Currently, there is no scientific evidence to suggest that the vaccines induce any hormonal changes that would lead to irregular periods. This had led some to wonder whether period changes may be a potential side effect of the vaccines. Most physicians say there is nothing to worry about and that the changes are temporary.

Vaccine 105

Vaccine Vaccination Protein Immune Response 105

XTalks

FEBRUARY 21, 2024

Tirzepatide’s mechanism of action involves activating two naturally produced hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Clinical Trials for MASH Treatment The tirzepatide trial involved approximately 190 adults with MASH at different stages.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. What does this Approval Mean for Breast Cancer Patients?

HR 52

HR Hormones FDA Approval Antibody 52

XTalks

AUGUST 22, 2024

Hypoparathyroidism arises when the parathyroid glands fail to produce enough parathyroid hormone (PTH) or when the PTH produced is ineffective. Yorvipath, developed using Ascendis Pharma’s TransCon technology, is the first and only approved treatment for hypoparathyroidism, marking this approval as a major milestone.

Hormones 52

Hormones FDA Approval Trials Clinical Trials 52

XTalks

JUNE 10, 2024

Efruxifermin is a novel Fc-FGF21 fusion protein designed to emulate the activity of native FGF21, an endogenous hormone that regulates metabolism and alleviates cellular stress. This comprehensive action of efruxifermin addresses the multifaceted nature of MASH.

Insulin 52

Insulin Life Science Regulation Hormones 52

XTalks

JUNE 27, 2022

Tafinlar and Mekinist Combination Clinical Trial Results. The safety and efficacy of the Tafinlar and Mekinist combination therapy was evaluated in three clinical trials. The safety profile of Tafinlar + Mekinist in these trials was consistent with data from its previous clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene 52

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The company’s menopause drug NT-814 is heading for phase 3 development in 2021 following a mid-stage trial readout.

Marketing 93

Marketing Gene Gene Silencing Drugs 93

XTalks

MAY 10, 2023

The exact cause of lupus is not entirely understood, but it is thought to be from a combination of genetic, environmental and hormonal factors. Investigational Drugs in Phase III Clinical Trials for Lupus There are a couple of investigational drugs that are new molecular entities (NME) in Phase III trials for lupus.

Drugs 52

Drugs Clinical Trials Clinical Trials Antibody 52

The Pharma Data

FEBRUARY 21, 2022

The company is advancing around 50 projects in ongoing clinical trials across a range of potential therapeutic modalities and indications, with a focus on oncology, cardiovascular and women’s health. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Clinical Trials Trials 40